Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

Impact · against what's priced in

Celcuity's updated VIKTORIA-1 data reveals a massive 12.4-month PFS advantage for the gedatolisib triplet over the standard of care in patients without liver metastases. This significant efficacy delta dramatically improves the clinical profile and commercial potential for the triplet therapy.

Scored by the NIS engine · methodology.

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

cancer research▲333%
clinical trials

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

What matters in this story

Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

What matters in this story

Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript

Track these names every morning.

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript

Darolutamidi yhdessä ADT- ja sädehoidon kanssa vähensi 58 prosentilla syövän leviämisen tai kuoleman vaaraa potilailla, joilla on suuri eturauhassyövän uusiutumisen riski

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

What matters in this story

Next reads from the same story arc

Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

What matters in this story

Next reads from the same story arc

Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript

Track these names every morning.

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript

Darolutamidi yhdessä ADT- ja sädehoidon kanssa vähensi 58 prosentilla syövän leviämisen tai kuoleman vaaraa potilailla, joilla on suuri eturauhassyövän uusiutumisen riski